Compare Medpace Holdings Inc (MEDP) vs MasTec Inc (MTZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs MasTec Inc — how do they compare? Medpace Holdings Inc trades at $612.05 (market cap $16.82B), while MasTec Inc trades at $212.65 (market cap $17.40B). The key difference: Medpace Holdings Inc and MasTec Inc are close in size by market cap, and Medpace Holdings Inc is trading nearer its 52-week high, MasTec Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Medpace Holdings Inc for 14 Days and MasTec Inc for 23 Days on average.
| MEDP | MTZ | |
|---|---|---|
Market Cap | $16.82B | $17.40B |
Volume | 223,093 | 1,415,821 |
Sector | Health | Industrials |
52-Week High | $630.19 | $437.51 |
52-Week Low | $393.42 | $190.08 |
Typical Hold Time | 14 Days | 23 Days |
Enterprise Value | $16.44B | $20.32B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MEDP trades at $612.05, up 1.29% today, near its consensus price target of $620.44. The stock shows strong profitability with a 17.67% net margin and has beaten earnings estimates for the last three quarters. Technical indicators are neutral overall, with support at $595 and resistance at $612. Recent news highlights CEO stock sales and institutional position changes, while the company prepares to report Q3 2026 results on October 21.
Outlook remains positive given consistent earnings beats and projected revenue growth to $2.8B in 2026. Risks include high valuation multiples (P/E 35.41) and insider selling. Analyst consensus is cautious with 79% hold ratings, suggesting limited near-term upside but solid fundamental support for long-term holders.
MasTec (MTZ) trades at $212.65, down 4.8% amid bearish technical signals, though recent earnings show mixed results with two beats and one miss. The company maintains strong analyst support with 88.9% buy ratings and a $408.58 consensus target, supported by record $21.4B backlog and infrastructure demand growth. Revenue reached $14.3B in 2025 with 3.07% net margin, while valuation ratios appear elevated with P/E of 34.5.
MTZ presents a compelling infrastructure growth story with AI and data center exposure, though premium valuation and weak cash flow pose near-term risks. The stock's current discount to analyst targets offers potential upside if execution improves, but investors should monitor communications segment softness and margin pressures in a competitive contracting environment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About MasTec Inc
MasTec, Inc. is a leading infrastructure construction company operating mainly in North America. The company's services cover a diverse range of end-markets, including communications (building fiber and wireless infrastructure), oil & gas, electric power (transmission, distribution, and clean energy), and industrial projects. MTZ provides critical engineering, procurement, and construction (EPC) services that support the expansion and maintenance of essential infrastructure across the continent.
Read more on MTZ →
